Prasugrel, a Third-Generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary Intervention: Phase III, randomized, double-blind study

Circulation Journal

Volumn 78, Issue 12, 2014, Pages 2926-2934

  Isshiki, Takaaki ^a   Kimura, Takeshi ^b   Ogawa, Hisao ^c   Yokoi, Hiroyoshi ^d   Nanto, Shinsuke ^e   Takayama, Morimasa ^f   Kitagawa, Kazuo ^e   Nishikawa, Masakatsu ^g   Miyazaki, Shunichi ^h   Ikeda, Yasuo ⁱ   Nakamura, Masato ^j   Saito, Shigeru ^k  

^a TEIKYO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f SAKAKIBARA HEART INSTITUTE   (Japan)

^g Institute of Human Research Promotion and Drug Development   (Japan)

^h KINKI UNIVERSITY   (Japan)

ⁱ WASEDA UNIVERSITY   (Japan)

^j TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^k SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

more..

Author keywords

Clopidogrel; Coronary artery disease; Elective percutaneous coronary intervention; Japanese; Prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; GENOMIC DNA; HEMOGLOBIN; PRASUGREL; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450 2C19; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE; TICLOPIDINE;

AGED; ALLELE; ARTICLE; BLEEDING; BRAIN INFARCTION; CARDIOVASCULAR MORTALITY; CORONARY ARTERY DISEASE; CYTOCHROME P450 2C19 GENE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GENE; GENETIC ANALYSIS; GENOTYPE; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; KAPLAN MEIER METHOD; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; SINGLE NUCLEOTIDE POLYMORPHISM; STABLE ANGINA PECTORIS; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; ANALOGS AND DERIVATIVES; BRAIN ISCHEMIA; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY DISEASE; DRUG EFFECTS; ELECTIVE SURGERY; FOLLOW UP; GENE FREQUENCY; GENETICS; HEMORRHAGE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MYOCARDIAL INFARCTION; POSTOPERATIVE COMPLICATIONS; STENT;

AGED; BRAIN ISCHEMIA; COMBINED MODALITY THERAPY; CORONARY DISEASE; CYTOCHROME P-450 CYP2C19; DOUBLE-BLIND METHOD; ELECTIVE SURGICAL PROCEDURES; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET AGGREGATION; POSTOPERATIVE COMPLICATIONS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; STENTS; THIOPHENES; TICLOPIDINE;

EID: 84911876473     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0266     Document Type: Article

References (17)

1. Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012; 60: 645-681.
2. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al. 2009 focused updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271-2306.
3. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
4. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 2009; 373: 309-317.
5. Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 2009; 103: 806-811.
6. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
7. Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. Circ J 2014; 78: 1684-1692.
8. Isshiki T, Kimura T, Ueno T, Nakamura M, Igarashi K, Yokoi H, et al. Clopidogrel trial in patients with elective percutaneous coronary intervention for stable angina and old myocardial infarction (CLEAN). Int Heart J 2012; 53: 91-101.
9. Price MJ. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 2009; 119: 2625-2632.
10. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Comparison of an everolimus-eluting stent and a paclitaxeleluting stent in patients with coronary artery disease: A randomized trial. JAMA 2008; 299: 1903-1913.
11. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, et al. Antiplatelet therapy and stent thrombosis after sirolimuseluting stent implantation. Circulation 2009; 119: 987-995.
12. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al; TAXUS-IV Investigators. A polymer-based, paclitaxeleluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
13. Turco MA, Ormiston JA, Popma JJ, Mandinov L, O'Shaughnessy CD, Mann T, et al. Polymer-based, paclitaxel-eluting TAXUS Liberté stent in de novo lesions: The pivotal TAXUS ATLAS trial. J Am Coll Cardiol 2007; 49: 1676-1683.
14. Sakurai R, Hongo Y, Yamasaki M, Honda Y, Bonneau HN, Yock PG, et al; ENDEAVOR II Trial Investigators. Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). Am J Cardiol 2007; 100: 818-823.
15. Nakata T, Miyahara M, Nakatani K, Wada H, Tanigawa T, Komada F, et al. Relationship between CYP2C19 loss-of-function polymorphism and platelet reactivities with clopidogrel treatment in Japanese patients undergoing coronary stent implantation. Circ J 2013; 77: 1436-1444.
16. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
17. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-1328.